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Summary objective The recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-
thamine to artemether-lumefantrine (AL) in Kenya was accompanied by revised malaria diagnosis
recommendations promoting presumptive antimalarial treatment in young children and parasitological
diagnosis in patients 5 years and older. We evaluated the impact of these age-speciﬁc recommendations
on routine malaria treatment practices 4–6 months after AL treatment was implemented.
methods Cross-sectional, cluster sample survey using quality-of-care assessment methods in all gov-
ernment facilities in four Kenyan districts. Analysis was restricted to the 64 facilities with malaria
diagnostics and AL available on the survey day. Main outcome measures were antimalarial treatment
practices for febrile patients stratiﬁed by age, use of malaria diagnostic tests, and test result.
results Treatment practices for 706 febrile patients (401 young children and 305 patients ‡5 years)
were evaluated. 43.0% of patients ‡5 years and 25.9% of children underwent parasitological malaria
testing (87% by microscopy). AL was prescribed for 79.7% of patients ‡5 years with positive test results,
for 9.7% with negative results and for 10.9% without a test. 84.6% of children with positive tests, 19.2%
with negative tests, and 21.6% without tests were treated with AL. At least one antimalarial drug was
prescribed for 75.0% of children and for 61.3% of patients ‡5 years with a negative test result.
conclusions Despite different recommendations for patients below and above 5 years of age, malaria
diagnosis and treatment practices were similar in the two age groups. Parasitological diagnosis was
under-used in older children and adults, and young children were still tested. Use of AL was low overall
and alternative antimalarials were commonly prescribed; but AL prescribing largely followed the results
of malaria tests. Malaria diagnosis recommendations differing between age groups appear complex to
implement; further strengthening of diagnosis and treatment practices under AL policy is required.
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Introduction
Antimalarial treatment with highly efﬁcacious but expen-
sive artemisinin-based combination therapy (ACT) is a
recent key strategy to reduce the public health impact of
failing monotherapies in sub-Saharan Africa (White 2006;
WHO 2006). In 2004, Kenya changed its ﬁrst-line
treatment policy for uncomplicated malaria from sulfa-
doxine-pyrimethamine (SP) to a speciﬁc ACT, artemether-
lumefantrine (AL). Quinine became the treatment of choice
for children below 5 kg, pregnant women, and as the
second-line; SP was reserved only for intermittent pre-
ventive treatment in pregnancy; and amodiaquine (previ-
ous second-line treatment) was no longer recommended
(MoH 2006a).
To rationalize the use of expensive ACTs, the WHO
promotes parasitological diagnosis, except for young
children in high malaria risk areas where, pending further
evidence, the clinical consequences associated with not
treating potentially false negative test results may outweigh
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(WHO) 2006). To support implementation of the new AL
policy, the Kenyan Ministry of Health (MoH) revised
recommendations for malaria diagnosis at facilities where
malaria microscopy or rapid diagnostic tests (RDT) are
available. Considering age-speciﬁc risks to clinical conse-
quences of malaria, age-speciﬁc probability of malaria
exposure, and the cost of AL treatment across different age
groups, the new diagnosis recommendations were reﬂected
in revised guidelines (Ministry of Health (MoH) 2006a). In
summary, the guidelines recommend that all febrile chil-
dren below 5 years of age in high malaria risk areas should
be presumptively treated with AL. All parts of Kenya are
classiﬁed as high malaria risk areas, except the highlands of
Central and Nairobi provinces. All febrile patients without
another obvious cause of fever aged ‡5 years should have a
malaria test performed, and health workers should treat for
malaria only patients who test positive.
In 2006 the new AL policy was implemented country-
wide and evaluated approximately 4–6 months after AL
was delivered to health facilities. Descriptions of the
implementation process and overall paediatric malaria
case-management results were published earlier (Amin
et al. 2007; Zurovac et al. 2008). We report here how age-
speciﬁc malaria diagnosis recommendations were trans-
lated into routine malaria treatment practices at facilities
with diagnostic capacity.
Methods
Between October and December 2006, we evaluated
outpatient malaria case-management at government health
facilities in four Kenyan districts (Kwale, Bondo, Kisii⁄
Gucha and Makueni). The detailed explanation of survey
methods is presented elsewhere (Zurovac et al. 2008).
Brieﬂy, the survey was a cross-sectional, cluster sample
survey undertaken at all 193 government facilities in the
four districts. Data at each facility were collected over
1 day using quality-of-care assessment methods including
health facility assessments, health worker interviews, and
exit interviews with caretakers and patients. During the
exit interviews the study nurses collected information
about patient’s age, weight, temperature, history of fever,
pregnancy status, main complaints, prior use of antima-
larial drugs and if the visit was an initial or follow-up
consultation. Information was also collected from patient-
held records about routine diagnostic procedures requested
and results reported, medications prescribed, and if the
patient was treated as an outpatient or referred for
hospitalization. The present analysis focused on routine
antimalarial treatment practices for patients weighing
‡5 kg presenting for an initial consultation and on outpa-
tient visit with a history of fever or axillary temperature
‡37.5  C. Pregnant women and patients ‡5 years present-
ing with another obvious cause of fever were excluded
from analysis. Since malaria diagnosis recommendations
differ between age groups, we stratiﬁed this analysis for
patients below and above 5 years of age. Treatment
practices were further stratiﬁed by use and results of
malaria tests. Given the small number of patients at
facilities with malaria RDTs, which precludes a meaningful
analysis stratiﬁed by type of diagnostics, the combined
results from all facilities are presented. To ensure compa-
rable evaluation of treatment practices, the analysis was
restricted to facilities where AL was available on the survey
day. The precision of proportions [95% conﬁdence interval
(CI)] was determined adjusting for the cluster sampling.
Results
Of 193 health facilities assessed, 70 (36.3%) had para-
sitological capacity for malaria diagnosis, more com-
monly providing malaria microscopy (55⁄70, 78.6%)
than RDTs (19⁄70, 27.1%). Only four facilities had both
diagnostic capacities. We analysed treatment practices for
706 febrile patients (401 < 5 years and 305 ‡ 5 years of
age) presenting to the 64 facilities with diagnostic support
where AL was in stock on the survey day. Of these
patients, the majority in each respective age group was
evaluated at facilities with microscopy (88.0% and 84.9%
respectively). Among patients ‡5 years, only 43.0% (95%
CI: 34.4–51.5) had a diagnostic test performed. At the
same facilities, 25.9% of children <5 years of age (95%
CI: 16.8–25.1) were tested. Positive malaria tests
were routinely reported for 50.0% of children (95% CI:
39.3–60.7) and 52.7% of patients ‡5 years (95% CI:
42.8–62.5).
The pattern of antimalarial treatments was similar
among febrile patients below and ‡5 years (Table 1). AL
was prescribed for 84.6% (95% CI: 71.5–97.7) of children
with positive test results, for 19.2% (95% CI: 5.8–32.7)
with negative results, and for 21.6% (95% CI: 8.3–34.8) of
children who were not tested. Among patients ‡5 years,
79.7% (95% CI: 64.1–95.3) of patients with positive tests
were treated with AL, while 9.7% (95% CI: 0.2–19.2) with
negative tests and 10.9% (95% CI: 4.8–17.0) without a
test were also treated with AL. Notably, in both age
groups, antimalarial treatment was prescribed for the
majority of patients with negative test results [75.0% (95%
CI: 60.2–89.8) of children and 61.3% (95% CI: 47.0–75.6)
of patients ‡5 years] and those without tests performed
[64.3% (95% CI: 54.9–73.7) of children and 50.0% (95%
CI: 39.4–60.6) of patients ‡5 years]. Across all patient
categories, except those with positive test results, amodi-
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antimalarial treatments and over 80% of patients were
treated with antibiotics (Table 1).
Discussion
Kenya’s policy to promote presumptive malaria diagnosis
in young children and parasitological testing in patients
‡5 years should have resulted in substantially different
patterns of malaria diagnostic and treatment practices
between these age groups. However, the only difference
found was somewhat higher use of malaria testing in
patients ‡5 years (43%) than in young children (27%). In
both age groups, any antimalarial drug was prescribed to
the majority of patients with a positive test (98–99%),
negative test (61–75%) and those without test performed
(50–64%). AL, however, was rarely prescribed for all
patients’ categories (10–22%), except for those with a
positive test result (80–85%).
The observed pattern is likely to reﬂect modalities of AL
implementation process in Kenya. Prior to the introduction
of ACTs, several studies in Kenya (Zurovac et al. 2006a)
and elsewhere (Barat et al. 1999; Holtz & Kachur 2000;
Reyburn et al. 2007) reported high rates of negative test
results treated with an antimalarial drug. As a response to
the concern that the continuation of this practice under AL
policy would waste new expensive drugs, particularly in
older age groups (Zurovac et al. 2006b), the new guide-
lines unambiguously discouraged this practice for patients
‡5 years (Ministry of Health (MoH) 2006a). Simulta-
neously, prompt and effective presumptive treatment of
young febrile children was promoted in line with interna-
tional recommendations (Gove 1997; World Health
Organisation (WHO) 2006). However, the translation of
new guidelines into clinical practice faced several chal-
lenges. Firstly, although the guidelines recommended the
use of malaria microscopy or RDTs for patients ‡5 years,
there was no decision taken to procure and supply RDTs
on larger scale. Secondly, the training of health workers
greatly emphasized the high cost of AL demanding its
rational use for test-positive adults using microscopy or
RDTs, with less focus on providing prompt AL treatment
for febrile children. Indeed, all health workers had been
trained how to perform RDTs, their potential in peripheral
facilities had been emphasized and even limited quantities
of RDTs were delivered for training purposes (MoH
2006b). Thirdly, training messages commonly included
incorrect information about expecting RDT supplies,
compulsory testing before prescribing AL for all age
groups, and adequate efﬁcacy of non-recommended anti-
malarials (Wasunna et al. 2008). Finally, the national
guidelines were somewhat ambiguous as they stated
‘parasitological diagnosis is not prerequisite for the treat-
ment’ in febrile children. Therefore, it was not surprising
that we found similar age-speciﬁc practices characterized
by suboptimal use of malaria diagnostics and prescription
of AL predominantly for the small subset of test positive
patients.
Antimalarial treatment practices for test negative older
children and adults deserve special attention. Although the
use of malaria diagnostics was low, our previous concerns
that health workers would massively overprescribe AL for
these patients appear to be unfounded (Zurovac et al.
2006a,b; Reyburn et al. 2006). The change of policy to AL
has not eliminated unnecessary use of other inexpensive
antimalarial drugs, but the new policy, however, had an
Table 1 Antimalarial treatment practices for febrile patients stratiﬁed by age and result of malaria test
Children below 5 years of age Patients 5 years and older
Positive
test
n = 52(%)
Negative
test
n = 52(%)
Test not
done
n = 297(%)
Total
n = 401(%)
Positive
test
n = 69(%)
Negative
test
n = 62(%)
Test not
done
n = 174(%)
Total
n = 305(%)
AL 44 (84.6) 10 (19.2) 64 (21.6) 118 (29.4) 55 (79.7) 6 (9.7) 19 (10.9) 80 (26.2)
AQ 5 (9.6) 18 (34.6) 97 (32.7) 120 (29.9) 3 (4.4) 17 (27.4) 37 (21.3) 57 (18.7)
SP 0 5 (9.6) 4 (1.4) 9 (2.2) 0 8 (12.9) 18 (10.3) 26 (8.5)
SP+AQ 1 (1.9) 5 (9.6) 14 (4.7) 20 (5.0) 1 (1.5) 4 (6.5) 13 (7.5) 18 (5.9)
QN 1 (1.9) 0 5 (1.7) 6 (1.5) 4 (5.8) 2 (3.2) 0 6 (2.0)
Other AM 0 1 (1.9) 7 (2.4) 8 (2.0)* 5 (7.3) 1 (1.6) 0 6 (2.0)
No AM prescribed 1 (1.9) 13 (25) 106 (35.7) 120 (29.9) 1 (1.5) 24 (38.7) 87 (50.0) 112 (36.7)
Any AM prescribed 51 (98.1) 39 (75.0) 191 (64.3) 281 (70.1) 68 (98.6) 38 (61.3) 87 (50.0) 193 (63.3)
Antibiotic prescribed 32 (61.5) 44 (84.6) 250 (84.2) 326 (81.3) 41 (59.4) 54 (87.1) 137 (78.7) 232 (76.1)
AL, artemether-lumefantrine; AQ, amodiaquine; SP, sulfadoxine-pyrimethamine; QN, quinine; AM, antimalarial.
*Other antimalarial treatments include QN+AL (3), AQ+QN (2), dehydroartemisinin (2) and artemether (1).
Other antimalarial treatments include QN+AL (1), AQ+QN (4) and dehydroartemisinin (1).
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Although this is an encouraging ﬁnding, it should be
cautiously interpreted since the pattern might change with
longer establishment of AL policy, removal of amodia-
quine from the facilities, and more widespread availability
of RDTs as demonstrated in Zambia (Hamer et al. 2007).
Conclusion
The translation of revised diagnostic recommendations into
effective malaria treatment practices under the AL policy in
Kenya faces several challenges. Parasitological diagnosis is
underused in older children and adults, young children are
stilltestedandtheoveralluseofALislowinbothagegroups
with marked tendency for alternative antimalarial prescrip-
tions. Prescribing of AL, however, largely followed malaria
test results. Different age-speciﬁc diagnosis recommenda-
tions appear complex to implement. The most suitable
solution for policy implementers would be to have the same
recommendations for all age groups. RDTs are a potential
solution for young children, as suggested recently in urban
setting inUganda(Njama-Meya et al. 2007); howevermore
evidence across different settings is required to document if
not treating test-negative children in high risk areas can
producesigniﬁcantcost-savingswithoutresultinginharmful
clinical consequences. Meanwhile, the priority for the
Kenyan MoH should be strengthening of AL implementa-
tion activities based on presumptive treatment for young
children and parasitological diagnosis, including RDTs, for
patients 5 years and older.
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